✦ LIBER ✦

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

✍ Scribed by Dev, I K; Dornsife, R E; Hopper, T M; Onori, J A; Miller, C G; Harrington, L E; Dold, K M; Mullin, R J; Johnson, J H; Crosby, R M

Book ID: 109998237
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 199 KB
Volume: 91
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6602109

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expression of receptor tyrosine kinases

Expression of receptor tyrosine kinases VEGFR-1 (FLT-1), VEGFR-2 (KDR), EGFR-1, PDGFRa and c-Met in canine primary brain tumours

✍ P. J. Dickinson; B. N. Roberts; R. J. Higgins; C. M. Leutenegger; A. W. Bollen; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

91 POSTER Impact of tumor VEGF expressio

91 POSTER Impact of tumor VEGF expression level on the in situ efficacy of the VEGFR2 associated tyrosine kinase inhibitor ZD6474

✍ D. Slemann; C. Norris 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Traceless Solid-Phase Synthesis of 2-Ami

Traceless Solid-Phase Synthesis of 2-Aminothiazoles: Receptor Tyrosine Kinase Inhibitors with Dual Selectivity for Tie-2 and VEGFR-2

✍ Frank Stieber; Ralph Mazitschek; Natascha Soric; Athanassios Giannis; Herbert Wa 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 2 views

Neovascularization in the human heart is

Neovascularization in the human heart is associated with expression of VEGF-A and its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2). Results from cardiomyopexy in ischemic cardiomyopathy

✍ Johannes Waltenberger; Andrea Kranz; Michael Beyer 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 205 KB

Levels of circulating CD45dimCD34+VEGFR2

Levels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

✍ Farace, F; Gross-Goupil, M; Tournay, E; Taylor, M; Vimond, N; Jacques, N; Billio 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 423 KB

139 BAY 57-9352: an inhibitor of VEGFR-2

139 BAY 57-9352: an inhibitor of VEGFR-2 and PDGFR receptor tyrosine kinases that demonstrates anti-angiogenic activity in vitro and in vivo

✍ J. Elting; R. Jones; C. Carter; C. Flynn; G. Zhu; C. Damico; M. McHugh; B. Hibne 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 146 KB